AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
TrumpRx: Enabling direct-to-patient care?
As of December 11, 2025, a variety of manufacturers have reached agreements or stated their intent to offer discounted prices for some of their medications...